Zobrazeno 1 - 3
of 3
pro vyhledávání: ''
Publikováno v:
Antibodies, Vol 7, Iss 3, p 30 (2018)
Antibodies
Volume 7
Issue 3
Antibodies
Volume 7
Issue 3
Monoclonal antibody (mAb) therapeutics have a promising outlook within the pharmaceutical industry having made positive strides in both research and development as well as commercialisation, however this development has been hampered by manufacturing
Publikováno v:
Antibodies
Volume 8
Issue 1
Antibodies, Vol 8, Iss 1, p 25 (2019)
Volume 8
Issue 1
Antibodies, Vol 8, Iss 1, p 25 (2019)
The FDA approval of two anti-HER2 monoclonal antibodies, trastuzumab and pertuzumab, and an antibody-drug conjugate, trastuzumab emtansine, has transformed clinical practice for HER2-positive cancers. However, not all patients respond to therapy, and
Autor:
Shih-Feng Cho, Lijie Xing, Liang Lin, Kenneth Wen, Yu-Tzu Tai, Tengteng Yu, Kenneth C. Anderson
Publikováno v:
Antibodies, Vol 6, Iss 4, p 18 (2017)
Antibodies
Antibodies
2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monocl